VivoSeq
Other

HCV Infection

0

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

HCV Infection is an early-stage landscape with 0 programs across 4 companies. The most active players are Gilead, Roche, Nanjing Sanhome Pharmaceutical, Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Gilead logo

Gilead

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalN

Nanjing Sanhome Pharmaceutical, Co., Ltd.

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

26

clinical trials

Completed22 · 85%
Unknown status3 · 12%
Active, not recruiting1 · 4%

Clinical Trials

Trial Activity

26 trials

Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia
Active, not recruiting·AANRS, Emerging Infectious Diseases·N/A·NCT05992077·21,000 enrolled
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
Completed·Gilead logoGilead·Phase 3·NCT02346721·111 enrolled
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection
Completed·Gilead logoGilead·Phase 3·NCT02220998·269 enrolled
Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Completed·Gilead logoGilead·Phase 3·NCT01682720·421 enrolled
Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
Completed·Gilead logoGilead·Phase 3·NCT01625338·534 enrolled
Response Guided Treatment With Direct Acting Anti-Viral Medications for Chronic HCV Infection
Completed·SSoroka University Medical Center·N/A·NCT03603327·30 enrolled
Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)
Completed·Gilead logoGilead·Phase 3·NCT01604850·202 enrolled
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
Completed·Gilead logoGilead·Phase 2·NCT01808248·47 enrolled
Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection
Completed·Gilead logoGilead·Phase 2·NCT01924949·5 enrolled
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection
Completed·Gilead logoGilead·Phase 3·NCT02201953·558 enrolled
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection
Completed·Gilead logoGilead·Phase 1·NCT01740791·103 enrolled
Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection
Completed·Gilead logoGilead·Phase 2·NCT01984294·101 enrolled
Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
Completed·Gilead logoGilead·Phase 2·NCT00743795·252 enrolled
Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection
Completed·Roche logoRoche·Phase 1·NCT00782353·35 enrolled
Short Course of Interferon Treatment in Patients With HCV Infection
Completed·—·Phase 4·NCT00502970·150 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)